RxDoctor Payments DataLook up a doctor →

Charles Bane, MD

Hematology & Oncology · Dayton, OHNPI 1730134933

Payments from drug & device makers

$1,307,791in general payments, 2019–2025

Across 1,055 payments — averaging $1239.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$619K
  • Beigene, Ltd.$346K
  • Novartis$177K
  • Exelixis Inc.$95K
  • Ferring International Pharmascience Center US$22K
  • Ferring Pharmaceuticals AS$20K
  • plus $28K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Daiichi Sankyo Inc.207$619,476
Beigene, Ltd.171$345,573
Novartis55$176,758
Exelixis Inc.19$94,970
Ferring International Pharmascience Center US14$22,474
Ferring Pharmaceuticals AS14$20,086
Bristol Myers Squibb17$9,557
Astrazeneca UK Limited1$5,323
Eli Lilly2$1,772
AstraZeneca(2 entities)37$1,674
Merck48$1,056
Johnson & Johnson(2 entities)44$675
AbbVie27$632
Genentech USA, Inc.27$536
Pfizer43$513
Pharmacyclics LLC, An Abbvie Company21$476
Incyte Corporation22$469
Bayer20$428
Tersera Therapeutics LLC13$353
Lilly USA, LLC14$278
Sanofi12$252
Gilead(2 entities)13$251
Regeneron Healthcare Solutions, Inc.13$234
Ipsen Biopharmaceuticals, Inc13$225
E.r. Squibb & Sons, L.L.C.12$211
Stemline Therapeutics Inc.9$205
Amgen13$204
Takeda Pharmaceuticals U.S.A., Inc.8$165
Eisai Inc.9$163
GSK8$154
ADC Therapeutics America, Inc.8$150
Varian Medical Systems, Inc.2$141
Astellas Pharma US Inc8$140
Beigene USA, Inc.7$133
Jazz Pharmaceuticals Inc.5$133
Array Biopharma Inc6$107
Sobi, Inc5$106
AVEO Pharmaceuticals, Inc.4$97
Genmab U.S., Inc.4$95
Adaptive Biotechnologies Corporation5$91
Foundation Medicine, Inc.3$83
Pharmaessentia USA Corporation4$81
Seagen Inc.4$79
Rigel Pharmaceuticals, Inc.5$75
Kyowa Kirin, Inc.4$73
Syndax Pharmaceuticals, Inc.4$71
Beone Medicines USA, Inc.2$70
Blueprint Medicines Corporation4$68
Deciphera Pharmaceuticals Inc.4$64
Servier Pharmaceuticals LLC3$57
Legend Biotech USA Inc.3$54
Karyopharm Therapeutics Inc.3$52
Cardinal Health 110 LLC1$49
Cumberland Pharmaceuticals, Inc.2$44
Apellis Pharmaceuticals, Inc.2$40
Springworks Therapeutics, Inc.1$39
Taiho Oncology, Inc.2$36
Agios Pharmaceuticals, Inc.2$32
Aurobindo Pharma USA, Inc.2$32
Puma Biotechnology, Inc.2$28

How this compares

$1,307,791 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio →

Medicare billing

Part B allowed, 2024
$2,969,030
Medicare patients
782
Services billed
100,552

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Dayton

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →